CoChat
Sign Up
Cited by 372Schizophrenia research and treatmentNeurotransmitter Receptor Influence on BehaviorMental Health and Psychiatry

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

5-HT2and D2Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation

Kapur, Shitij, Zipursky, Robert B., Remington, Gary, Jones, Corey, DaSilva, Jean, Wilson, Alan A., Houle, Sylvain·1998·American Journal of Psychiatry
DOI 10.1176/ajp.155.7.921
Open this paper in CoChat — free account

Abstract

OBJECTIVE: Olanzapine is a new atypical antipsychotic recently introduced for the treatment of schizophrenia. The purpose of this study was to investigate olanzapine's binding to the serotonin 5-HT2 and dopamine D2 receptors in schizophrenic patients being treated with clinically relevant doses. METHOD: Twelve patients with schizophrenia were randomly assigned to 5, 10, 15, or 20 mg/day of olanzapine in a prospective fashion. Three other subjects taking 30-40 mg/day were also included. Once steady-state plasma levels were achieved, dopamine D2 and serotonin 5-HT2 receptors were assessed by using [11C]raclopride and [18F]setoperone positron emission tomography imaging, respectively. Ratings of clinical status, extrapyramidal side effects, and prolactin levels were also obtained. RESULTS: Olanzapine induced near saturation of the 5-HT2 receptors, even at 5 mg/day. Its D2 occupancy increased with dose: patients taking 5-20 mg/day showed 43%-80% D2 occupancy, while patients taking 30-40 mg/day showed 83%-88%. CONCLUSIONS: Olanzapine is a potent 5-HT2 blocker and shows a higher 5-HT2 than D2 occupancy at all doses. However, its D2 occupancy is higher than that of clozapine and similar to that of risperidone. In the usual clinical dose range of 10-20 mg/day, its occupancy varies from 71% to 80%, and this restricted range may explain its freedom from extrapyramidal side effects and prolactin elevation. However, doses of 30 mg/day and higher are associated with more than 80% D2 occupancy and may have a higher likelihood of prolactin elevation and extrapyramidal side effects.

Overview

Integrity signals

Registry

Crossref · 10.1176/ajp.155.7.921

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Flagged first, then by citations

Show all 41 references

Research works printed but not linked: 1

  1. Janicak P, Javaid J, Sharma R, Leach A, Easton M, Dowd S, Davis J, Dowd S, Davis J: Haloperidol dose/response relationship—results from a random-assignment, double blind study (abstract). Neuropsychopharmacology 1994; 10:106S

Cited by

Sorted by citations

Items 201–300 of 372

Related

See all

Metadata

Authors
Kapur, S., Zipursky, R. B., Remington, G., Jones, C., DaSilva, J., Wilson, A. A., & Houle, S.
ORCID
Venue
American Journal of Psychiatry
Publisher
American Psychiatric Association Publishing
Published
1998-07-01
Volume
155
Issue
7
Pages
921-928
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
DOI
10.1176/ajp.155.7.921
OpenAlex
W2163010981
Cited by
370
References
41
Citations by year
2026: 5 · 2025: 7 · 2024: 9 · 2023: 9 · 2022: 8 · 2021: 4 · 2020: 10 · 2019: 5 · 2018: 7 · 2017: 6 · 2016: 8 · 2015: 7 · 2014: 9 · 2013: 19 · 2012: 14
FWCI
15.00
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Keywords
olanzapine, schizophrenia, dopamine D2 receptor occupancy, atypical antipsychotics, dose dependence, extrapyramidal symptoms, prolactin elevation, [11C]raclopride, clozapine, risperidone
MeSH terms
Olanzapine, Adult, Benzodiazepines, Carbon Radioisotopes, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Fluorine Radioisotopes, Humans, Male, Pirenzepine, Prolactin, Pyrimidinones, Receptors, Serotonin, Salicylamides, Schizophrenia, Tomography, Emission-Computed, Antipsychotic Agents, Treatment Outcome, Receptors, Dopamine D2, Raclopride

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review